Antiangiogenic drugs
US6492330B1 · kind B1 · utility
5Cited by
6References
33Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Feb 11, 1999 |
| Grant date | Dec 10, 2002 |
| Priority date | — |
| Expiry date | Feb 11, 2019 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/095
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to the use of peptides individually or in combination, for treating and/or preventing angiogenesis. It also relates to the use of peptide analogs or a combination of peptides referred to as MuJ-7 as anticancer drugs in restricting the tumor growth and spread by inhibiting tumor angiogenesis. MuJ-7, in addition inhibits metastasis through its antiangiogenic activity in all cancers. The invention also relates to a pharmaceutical composition containing either individual peptides or in combination, and methods of treatment of human beings and animals for curing and/or preventing angiogenesis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.